{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,2]],"date-time":"2025-08-02T14:55:06Z","timestamp":1754146506929,"version":"3.41.2"},"reference-count":33,"publisher":"IntechOpen","isbn-type":[{"type":"print","value":"9781836345725"},{"type":"electronic","value":"9781836345718"}],"license":[{"start":{"date-parts":[[2025,4,30]],"date-time":"2025-04-30T00:00:00Z","timestamp":1745971200000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/3.0\/legalcode"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"abstract":"<jats:p>Radiotherapy is an integral component in the treatment of oral cancers. It is commonly used either as a primary treatment or in combination with surgery and chemotherapy. The complex anatomy of the oral cavity and its proximity to critical structures, such as the salivary glands, mandible, and surrounding soft tissues, necessitate precise targeting and advanced techniques to maximize tumor control while minimizing damage to healthy tissue. These advanced techniques include Intensity Modulated Radiotherapy (IMRT), Volumetric Modulated Arc Therapy (VMAT), and Adaptive Radiotherapy (ART). IMRT allows for highly conformal dose distribution, enabling high radiation doses to be delivered to the tumor while sparing surrounding normal tissues, such as the salivary glands, jawbone, and oral mucosa. VMAT is a faster technique compared to IMRT and can be advantageous in terms of reduced treatment time, fewer setup errors, and more comfort for the patients. Further research into personalized treatment approaches and the integration of new technologies can contribute to better patient outcomes and quality of life.<\/jats:p>","DOI":"10.5772\/intechopen.1010304","type":"book-chapter","created":{"date-parts":[[2025,5,21]],"date-time":"2025-05-21T04:41:46Z","timestamp":1747802506000},"source":"Crossref","is-referenced-by-count":0,"title":["Advanced Radiotherapy Techniques in Oral Cancer"],"prefix":"10.5772","author":[{"given":"Shraddha","family":"Srivastava","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shally","family":"Batham","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seema","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"3774","published-online":{"date-parts":[[2025,4,30]]},"reference":[{"key":"ref=1","doi-asserted-by":"crossref","unstructured":"Bray F, Laversanne M, Sung H, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: A Cancer Journal for Clinicians. 2024;74(3):229-263","DOI":"10.3322\/caac.21834"},{"key":"ref=2","unstructured":"Ribeiro FAP, Noguti J, Oshima CTF, Ribeiro DA. Effective targeting of the epidermal growth factor receptor (EGFR) for treating oral cancer: A pro mising approach. Anticancer Research. 2014;34:1547-1552"},{"key":"ref=3","doi-asserted-by":"crossref","unstructured":"Liu F, Millar S. Wnt\/\u03b2-catenin signaling in oral tissue development and dis ease. Journal of Dental Research. 2010;89:318-330","DOI":"10.1177\/0022034510363373"},{"key":"ref=4","doi-asserted-by":"crossref","unstructured":"Huang J-S et al. Honokiol inhibits sphere formation and xenograft growth of oral cancer side population cells accompanied with JAK\/STAT signaling pathway suppression and apoptosis induction. BMC Cancer. 2016;16:1-13","DOI":"10.1186\/s12885-016-2265-6"},{"key":"ref=5","doi-asserted-by":"crossref","unstructured":"Ali J et al. Genetic etiology of oral cancer. Oral Oncology. 2017;70:23-28","DOI":"10.1016\/j.oraloncology.2017.05.004"},{"key":"ref=6","doi-asserted-by":"crossref","unstructured":"Simpson DR, Mell LK, Cohen EEW. Targeting the PI3K\/AKT\/mTOR pathway in squamous cell carcinoma of the head and neck. Oral Oncology. 2015;51:291-298","DOI":"10.1016\/j.oraloncology.2014.11.012"},{"key":"ref=7","doi-asserted-by":"crossref","unstructured":"Speight PM et al. Screening for oral cancer\u2014A perspective from the global oral cancer forum. Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology. 2017;123:680-687","DOI":"10.1016\/j.oooo.2016.08.021"},{"key":"ref=8","doi-asserted-by":"crossref","unstructured":"Zhang J et al. Attenuated TRAF3 fosters activation of alternative NF-\u03baB and reduced expression of antiviral interferon, TP53, and RB to promote HPV positive head and neck cancers decreased TRAF3 promotes HPV+ HNSCC. Cancer Research. 2018;78:4613-4626","DOI":"10.1158\/0008-5472.CAN-17-0642"},{"key":"ref=9","doi-asserted-by":"crossref","unstructured":"Vijayalakshmi N, Selvaluxmi G, Majhi U, Rajkumar T. Alterations found in p16\/RB\/Cyclin D1 pathway in the dysplastic and malignant cervical epithelium. Oncology Research. 2007;16:527-533","DOI":"10.3727\/096504007783438367"},{"key":"ref=10","doi-asserted-by":"crossref","unstructured":"Shridhar K et al. DNA methylation markers for oral pre-cancer progression: A critical review. Oral Oncology. 2016;53:1-9","DOI":"10.1016\/j.oraloncology.2015.11.012"},{"key":"ref=11","doi-asserted-by":"crossref","unstructured":"Wang Y et al. The histone demethylase LSD1 is a novel oncogene and therapeutic target in oral cancer. Cancer Letters. 2016;374:12-21","DOI":"10.1016\/j.canlet.2016.02.004"},{"key":"ref=12","doi-asserted-by":"crossref","unstructured":"Portney BA et al. ZSCAN4 facilitates chromatin remodeling and promotes the cancer stem cell phenotype. Oncogene. 2020;39:4970-4982","DOI":"10.1038\/s41388-020-1333-1"},{"key":"ref=13","doi-asserted-by":"crossref","unstructured":"Irimie AI et al. A looking-glass of non-coding RNAs in oral cancer. International Journal of Molecular Sciences. 2017;18:2620","DOI":"10.3390\/ijms18122620"},{"key":"ref=14","doi-asserted-by":"crossref","unstructured":"Gr\u00e9goire V et al. Delineation of the neck node levels for head and neck tumors: A 2013 update. DAHANCA, EORTC, HKNPCSG, NCIC CTG, NCRI, RTOG, TROG consensus guidelines. Radiotherapy and Oncology;110(1):172-181","DOI":"10.1016\/j.radonc.2013.10.010"},{"key":"ref=15","doi-asserted-by":"crossref","unstructured":"Fu KK, Pajak TF, Trotti A, Jones CU, Spencer SA, Phillips TL, et al. A radiation therapy oncology group (RTOG) phase III randomized study to compare hyperfractionation and two variants of accelerated fractionation to standard fractionation radiotherapy for head and neck squamous cell carcinomas: First report of RTOG 9003. International Journal of Radiation Oncology, Biology, Physics. 2000;48:7-16","DOI":"10.1016\/S0360-3016(00)00663-5"},{"key":"ref=16","doi-asserted-by":"crossref","unstructured":"Connell PP, Hellman S. Advances in radiotherapy and implications for the next century: A historical perspective. Cancer Research. 2009;69(2):383-392","DOI":"10.1158\/0008-5472.CAN-07-6871"},{"key":"ref=17","doi-asserted-by":"crossref","unstructured":"Batham S, Gupta S, Ghosh A, Gupta IJ, Johny D, Srivastava S, et al. Comparative study of dysphagia-optimized intensity modulated radiotherapy (do-IMRT) and standard intensity modulated radiotherapy (S-IMRT) and its clinical correlation in head and neck cancer patients. Asian Pacific Journal of Cancer Prevention. 2023;24(11):3697-3704","DOI":"10.31557\/APJCP.2023.24.11.3697"},{"key":"ref=18","doi-asserted-by":"crossref","unstructured":"Ahmed M, Hansen VN, Harrington KJ, Nutting CM. Reducing the risk of xerostomia and mandibular osteoradionecrosis: The potential benefits of intensity modulated radiotherapy in advanced oral cavity carcinoma. Medical Dosimetry. 2009;34:217-224","DOI":"10.1016\/j.meddos.2008.08.008"},{"key":"ref=19","unstructured":"Miah AB, Bhide SA, Guerrero-Urbano MT, et al. Bilateral superficial lobe parotid sparing IMRT: Treating base of tongue tumours: Similar outcomes to unilateral whole parotid gland sparing. Radiotherapy and Oncology. 2009;90(Suppl. 2):S11"},{"key":"ref=20","doi-asserted-by":"crossref","unstructured":"Chen WC, Hwang TZ, Wang WH, Lu CH, Chen CC, Chen CM, et al. Comparison between conventional and intensity-modulated post-operative radiotherapy for stage III and IV oral cavity cancer in terms of treatment results and toxicity. Oral Oncology. 2009;45:505-510","DOI":"10.1016\/j.oraloncology.2008.07.002"},{"key":"ref=21","doi-asserted-by":"crossref","unstructured":"Gomez DR, Zhung JE, Gomez J, Chan K, Wu AJ, Wolden SL, et al. Intensity-modulated radiotherapy in postoperative treatment of oral cavity cancers. International Journal of Radiation Oncology, Biology, Physics. 2009;73:1096-1103","DOI":"10.1016\/j.ijrobp.2008.05.024"},{"key":"ref=22","doi-asserted-by":"crossref","unstructured":"Nutting CM, Morden JP, Harrington KJ, Urbano TG, Bhide SA, Clark C, et al. Parotid-sparing intensity modulated versus conventional radiotherapy in head and neck cancer (PARSPORT): A phase 3 multicentre randomised controlled trial. The Lancet Oncology. 2011;12:127-136","DOI":"10.1016\/S1470-2045(10)70290-4"},{"key":"ref=23","doi-asserted-by":"crossref","unstructured":"Vanetti E, Clivio A, Nicolini G, Fogliata A, Ghosh-Laskar S, Agarwal JP, et al. Volumetric modulated arc radiotherapy for carcinomas of the oro-pharynx, hypo-pharynx and larynx: A treatment planning comparison with fixed field IMRT. Radiotherapy and Oncology. 2009;92:111-117","DOI":"10.1016\/j.radonc.2008.12.008"},{"key":"ref=24","doi-asserted-by":"crossref","unstructured":"Lee TF, Chao PJ, Ting HM, Lo SH, Wang YW, Tuan CC, et al. Comparative analysis of SmartArc-based dual arc volumetric-modulated arc radiotherapy (VMAT) versus intensity-modulated radiotherapy (IMRT) for nasopharyngeal carcinoma. Journal of Applied Clinical Medical Physics. 2011;12:3587. DOI: 10.1120\/jacmp.v12i4.3587","DOI":"10.1120\/jacmp.v12i4.3587"},{"key":"ref=25","doi-asserted-by":"crossref","unstructured":"Holt A, Van Gestel D, Arends MP, Korevaar EW, Schuring D, Kunze-Busch MC, et al. Multi-institutional comparison of volumetric modulated arc therapy vs. intensity-modulated radiation therapy for head-and-neck cancer: A planning study. Radiation Oncology. 2013;8:26","DOI":"10.1186\/1748-717X-8-26"},{"key":"ref=26","doi-asserted-by":"crossref","unstructured":"Morgan HE, Sher DJ. Adaptive radiotherapy for head and neck cancer. Cancers of the Head &amp; Neck. 2020;5:1","DOI":"10.1186\/s41199-019-0046-z"},{"key":"ref=27","doi-asserted-by":"crossref","unstructured":"Schwartz DL, Dong L. Adaptive radiation therapy for head and neck cancer-can an old goal evolve into a new standard? Journal of Oncology. 2011;2011:690595","DOI":"10.1155\/2011\/690595"},{"key":"ref=28","doi-asserted-by":"crossref","unstructured":"Chen AM, Daly ME, Cui J, Mathai M, Benedict S, Purdy JA. Clinical outcomes among patients with head and neck cancer treated by intensity-modulated radiotherapy with and without adaptive replanning. Head &amp; Neck. 2014;36(11):1541-1546","DOI":"10.1002\/hed.23477"},{"key":"ref=29","doi-asserted-by":"crossref","unstructured":"Huang SH, O'Sullivan B. Oral cancer: Current role of radiotherapy and chemotherapy. Medicina Oral, Patolog\u00eda Oral y Cirug\u00eda Bucal. 2013;18(2):e233-e240","DOI":"10.4317\/medoral.18772"},{"key":"ref=30","doi-asserted-by":"crossref","unstructured":"Babu S, Krishnan M. Radiant advances: The future of brachytherapy in oral oncology. Oral Oncology Reports. 2024;12:100654","DOI":"10.1016\/j.oor.2024.100654"},{"key":"ref=31","doi-asserted-by":"crossref","unstructured":"Mendenhall WM, Van Cise WS, Bova FJ, Million RR. Analysis of time-dose factors in squamous cell carcinoma of the oral tongue and floor of mouth treated with radiation therapy alone. International Journal of Radiation Oncology, Biology, Physics. 1981;7:1005-1011","DOI":"10.1016\/0360-3016(81)90151-6"},{"key":"ref=32","doi-asserted-by":"crossref","unstructured":"Wendt CD, Peters LJ, Delclos L, et al. Primary radiotherapy in the treatment of stage I and II oral tongue cancers: Importance of the proportion of therapy delivered with interstitial therapy. International Journal of Radiation Oncology, Biology, Physics. 1990;18:1287-1292","DOI":"10.1016\/0360-3016(90)90299-Y"},{"key":"ref=33","doi-asserted-by":"crossref","unstructured":"Ichimiya Y, Fuwa N, Kamata M, et al. Treatment results of stage I oral tongue cancer with definitive radiotherapy. Oral Oncology. 2005;41:520-525","DOI":"10.1016\/j.oraloncology.2004.12.012"}],"container-title":["Oncology","Advancements in Oral Cancer - Modern Diagnostics, Altered Molecular Profile and Therapeutic Strategies"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/intech-files.s3.amazonaws.com\/a043Y00000yuj66QAA\/a09Tc000001mYWfIAM\/Final-Advanced%20Radiotherapy%20Techniques%20in%20Oral%20Cancer%20%282025-06-14%2021%3A15%3A53%29.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,18]],"date-time":"2025-07-18T11:33:44Z","timestamp":1752838424000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.intechopen.com\/chapters\/1213657"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,30]]},"ISBN":["9781836345725","9781836345718"],"references-count":33,"URL":"https:\/\/doi.org\/10.5772\/intechopen.1010304","relation":{},"ISSN":["3049-8864"],"issn-type":[{"type":"print","value":"3049-8864"}],"subject":[],"published":{"date-parts":[[2025,4,30]]}}}